Company Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States.
The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia.
The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.
bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
| Country | United States |
| Founded | 1992 |
| IPO Date | Jun 19, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 375 |
| CEO | Andrew Obenshain |
Contact Details
Address: 455 Grand Union Boulevard Somerville, Massachusetts 02145 United States | |
| Phone | 339 499 9300 |
| Website | bluebirdbio.com |
Stock Details
| Ticker Symbol | BLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001293971 |
| CUSIP Number | 09609G100 |
| ISIN Number | US09609G1004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Obenshain | President, Chief Executive Officer and Director |
| Thomas J. Klima | Chief Commercial Officer and Chief Operating Officer |
| Richard A. Colvin M.D., Ph.D. | Chief Medical Officer |
| Oliver James Sterling III | Chief Financial Officer and Principal Accounting Officer |
| Joseph D. Vittiglio Esq., J.D. | Chief Legal and Business Officer and Secretary |
| Jess Rowlands | Head of Corporate Communications |
| Andrea Walton | Chief People Officer |
| Kasra Kasraian | Senior Vice President of Technical Development and Operations |
| Scott Shoemaker | Senior Vice President of Quality |
| Sarah Alspach | Senior Vice President of External Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 4, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Sep 27, 2024 | 10-Q | Quarterly Report |
| Sep 26, 2024 | ARS | Filing |
| Sep 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 26, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 24, 2024 | 8-K | Current Report |